BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26999572)

  • 1. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
    Cavazzini F; Lista E; Quaglia FM; Formigaro L; Cavallari M; Martinelli S; Rigolin GM; Foà R; Cuneo A
    Leuk Lymphoma; 2016 Nov; 57(11):2685-8. PubMed ID: 26999572
    [No Abstract]   [Full Text] [Related]  

  • 2. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
    Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
    Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
    Lacerda MP; Guedes NR; Yamakawa PE; Pereira AD; Fonseca ARBMD; Chauffaille MLLF; Goncalves MV; Yamamoto M; Rodrigues CA
    Ann Hematol; 2017 Sep; 96(9):1577-1578. PubMed ID: 28597168
    [No Abstract]   [Full Text] [Related]  

  • 4. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
    Mikudina B; Goodall M; Adler AI
    Lancet Oncol; 2017 Mar; 18(3):289-290. PubMed ID: 28130034
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
    Molica S; Levato L; Mirabelli R
    Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
    Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
    Molica S; Polliack A
    Leuk Res; 2016 Nov; 50():31-36. PubMed ID: 27657651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
    Montillo M; O'Brien S; Tedeschi A; Byrd JC; Dearden C; Gill D; Brown JR; Barrientos JC; Mulligan SP; Furman RR; Cymbalista F; Plascencia C; Chang S; Hsu E; James DF; Hillmen P
    Blood Cancer J; 2017 Feb; 7(2):e524. PubMed ID: 28157216
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
    Suzuki T; Miyakoshi S; Nanba A; Uchiyama T; Kawamoto K; Aoki S
    J Clin Exp Hematop; 2018 Sep; 58(3):136-140. PubMed ID: 30012921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.
    Rider TG; Grace RJ; Newman JA
    Br J Haematol; 2016 Apr; 173(2):326-7. PubMed ID: 26195269
    [No Abstract]   [Full Text] [Related]  

  • 11. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.
    Danilov AV
    Br J Haematol; 2016 Apr; 173(2):327-8. PubMed ID: 26195155
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
    Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
    Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
    Manda S; Dunbar N; Marx-Wood CR; Danilov AV
    Br J Haematol; 2015 Sep; 170(5):734-6. PubMed ID: 25716177
    [No Abstract]   [Full Text] [Related]  

  • 15. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
    Teh BW; Chui W; Handunnetti S; Tam C; Worth LJ; Thursky KA; Slavin MA
    Leuk Lymphoma; 2019 Jun; 60(6):1572-1575. PubMed ID: 30632838
    [No Abstract]   [Full Text] [Related]  

  • 16. Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report.
    Sachanas S; Pangalis GA; Karouzakis P; Koulieris E; Moschogiannis M; Kalpadakis C; Yiakoumis X; Rontogianni D
    Anticancer Res; 2016 Sep; 36(9):4759-62. PubMed ID: 27630324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
    Mannis G; Wu D; Dea T; Mauro T; Hsu G
    Am J Hematol; 2015 Feb; 90(2):179. PubMed ID: 24890909
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal management of the young patient CLL patient.
    Allan JN; Furman RR
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):73-82. PubMed ID: 29452669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
    Boudin L; Patient M; Tsitsi Nding Tsogou P; Roméo E; Bladé JS; de Jauréguiberry JP
    Bull Cancer; 2019 Jan; 106(1):84-85. PubMed ID: 30579570
    [No Abstract]   [Full Text] [Related]  

  • 20. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
    Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.